4.6 Review

Pyoderma gangrenosum: A review and update on new therapies

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 62, Issue 4, Pages 646-654

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2009.05.030

Keywords

adalimumab; alefacept; clinical trials; efalizumab; etanercept; infliximab

Categories

Funding

  1. Galderma Laboratories LP

Ask authors/readers for more resources

Pyoderma gangrenosum is a rare and often painful skin disease that can be unpredictable in its response to treatment. There is currently no gold standard of treatment or published algorithm for choice of therapy. The majority of data comes from case studies that lack a standard protocol not only for treatment administration but also for the objective assessment of lesion response to a specific therapy. This review provides an update to the treatment of pyoderma gangrenosum with a particular focus on new systemic therapies. (J Am Acad Dermatol 2010:62:646-54.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available